ModifiedUnitedHealthcarePolicy IEXD0036.09

Somatostatin Analogs (octreotide, lanreotide, pasireotide) — Medical Benefit Drug Policy

Medical benefit drug policy governing medical necessity and coverage criteria for somatostatin analogs for Individual Exchange plans (excludes MA, NV, NY); addresses agents such as octreotide, lanreotide, and pasireotide.

Policy Summary

PayerUnitedHealthcare

PolicySomatostatin Analogs (octreotide, lanreotide, pasireotide)

Policy CodePolicy IEXD0036.09

Change TypeCoverage rationale and indication clarificationscode removals

Effective DateApr 1, 2025

Next Review Date

Key ActionObtain prior authorization with diagnosis, prior therapies and response, and biochemical data (GH and IGF-1) to support medical necessity for long-acting somatostatin analog therapy.

SourceLink

POLICY UPDATE CHANGES

Added language to indicate Somatostatin analogs are unproven and not medically necessary for treating HIV-AIDS-related diarrhea.

Added language that Sandostatin and Sandostatin LAR are proven for treatment of severe diarrhea and flushing episodes associated with metastatic carcinoid tumors and profuse watery diarrhea associated with VIPomas.

Replaced prior broader wording to specify Sandostatin and Sandostatin LAR are proven for acromegaly only for patients who have had inadequate response to or cannot be treated with surgery, pituitary irradiation, or dopamine agonist therapy.

Replaced language for Signifor and Signifor LAR to indicate they are proven for Cushing's disease in patients for whom pituitary surgery is not an option or has not been curative, and for Signifor LAR for acromegaly patients with inadequate response to or who cannot undergo surgery.

Removed medical necessity criteria for acromegaly, bleeding gastroesophageal varices, and refractory HIV/AIDS-related diarrhea (various agents).

Somatuline Depot and lanreotide injection indication wording changed to specify acromegaly patients with inadequate response to surgery and/or radiotherapy or for whom surgery/radiotherapy is not an option.

3Branded therapies listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Proven / covered indications

Covered when ALL of the following apply for the specified indication:

Covered Indications: Acromegaly: patient has a confirmed diagnosis of acromegaly AND documentation that the patient has had an inadequate response to or is not a candidate for surgical resection and/or pituitary irradiation (and for Sandostatin/Sandostatin LAR, inability to be treated with dopamine agonist therapy is noted when applicable).GH <=2.5 µg/L target and IGF-1 normalized (trial-defined biochemical control)

Supported by product labeling and policy revision specifying acromegaly indications (see prescribing information).

Covered Indications: Carcinoid syndrome: severe diarrhea and flushing associated with metastatic carcinoid tumors for symptomatic control (reduces frequency of short-acting somatostatin rescue therapy).none

Indication supported by Sandostatin and Somatuline Depot labeling.

Covered Indications: VIPoma-associated profuse watery diarrhea: symptomatic treatment of vasoactive intestinal peptide (VIP)-secreting tumors.none

Supported by Sandostatin labeling.

Covered Indications: GEP‑NETs (Somatuline Depot/Lanreotide Injection): unresectable, well- or moderately-differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors to improve progression-free survival.none

As described in Somatuline and lanreotide product labeling.

Covered Indications: Bleeding gastroesophageal varices, chemotherapy- and/or radiation-induced diarrhea, malignant bowel disease (including malignant bowel obstruction) when used for symptomatic management as described in clinical evidence and policy rationale.none

Supporting evidence and pilot/registry data summarized in policy.

Cushing's disease (pasireotide/Signifor): Patient has confirmed Cushing's disease AND pituitary surgery is not an option or surgery was not curative.none

Signifor/Signifor LAR labeled indication for Cushing's disease when surgery not an option or not curative.

Unproven / Not medically necessary indications

Not covered / considered unproven when ANY of the following indications are the sole rationale:

Unproven Indications: Refractory HIV-AIDS-related diarrhea (use of somatostatin analogs is considered unproven and not medically necessary).

Explicitly added to the policy's exclusions in the 04/01/2025 revision.

Unproven Indications: Chylothorax (neonates/children/adults) when used as the sole justification — evidence consists mainly of case reports/series and RCT data are lacking.

Cochrane review and systematic reviews report insufficient RCT evidence.

Unproven Indications: Dumping syndrome when claimed as the primary indication for long-term therapy (short-term symptom control possible but long-term benefit limited by side effects).

Long-term efficacy limited; many patients discontinue due to side effects or loss of efficacy.

Indication-specific evidence summaries

Summarized evidence-based coverage considerations by indication (evidence excerpts only):

Malignant bowel obstruction: Randomized pilot (n=64) showed a non-significant signal favoring octreotide LAR + IR octreotide versus placebo; higher response in patients with Karnofsky ≥50; tolerability acceptable but high withdrawal/mortality related to disease severity.

See randomized pilot study results.

Refractory HIV/AIDS-related diarrhea: Open-label series (n=51) reported significant reductions in stool frequency/volume with 41.2% partial/complete responses; randomized trial (n=129) showed no overall benefit except possible improvement in very high baseline stool-weight subgroup; evidence mixed and limited.

Small nonrandomized and randomized data with subgroup signals.

Chylothorax: Evidence mainly case reports/series and small retrospective reviews with mixed outcomes; Cochrane review found no randomized trials and could not make practice recommendations.

Randomized trials lacking; further study needed.

Initial Therapy and Indication-aligned Coverage

Covered when meeting FDA-indicated diagnosis and clinical circumstances shown in trials/guidelines

Acromegaly - long-acting SRL: Member has confirmed acromegaly AND documentation that prior definitive therapies were attempted or are not possible (inadequate response to or unable to undergo surgery and/or radiotherapy) AND biochemical data (GH and IGF-1) consistent with active disease. Choice of long-acting SRL should align with prior therapy, efficacy data, and safety considerations (notably pasireotide glycemic risk).GH <= 2.5 µg/L target and IGF-1 normalized (trial-defined targets)

Supported by Endocrine Society and Pituitary Society guidance and product labeling; trials (PAOLA, Colao) inform agent selection and hyperglycemia risk.

Cushing's disease - pasireotide: Member has confirmed Cushing's disease AND pituitary surgery is not an option or surgery was not curative. Clinical documentation should include urinary free cortisol and other endocrine assessments per labeling.none

Signifor/Signifor LAR indicated for Cushing's disease when surgery not an option or not curative; trials show cortisol reductions but frequent hyperglycemia events.

Covered indications (as revised)

Covered when INDICATION-SPECIFIC conditions are met as described in prescribing information and policy rationale

Approved indications (revised): Somatostatin analogs are described as proven for: (1) long-term treatment of acromegaly in patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy (Sandostatin/Sandostatin LAR, Somatuline Depot, Lanreotide Injection, Signifor LAR where applicable); (2) treatment of unresectable, well- or moderately-differentiated, locally advanced or metastatic GEP‑NETs to improve progression-free survival (Somatuline Depot/Lanreotide Injection); (3) symptomatic control in carcinoid syndrome (reduces need for short-acting rescue therapy) and profuse watery diarrhea associated with VIPomas; and (4) Cushing's disease with pasireotide when surgery is not an option or not curative.

Revisions clarified and limited indications per 04/01/2025 policy history; statements reflect prescribing information.

Unproven / Not Medically Necessary

Not covered / Not medically necessary

Unproven indication: Use of somatostatin analogs for refractory HIV-AIDS-related diarrhea is considered unproven and not medically necessary.

Explicitly added to coverage rationale in the 04/01/2025 revision and policy exclusions.

Other unproven uses: Use for conditions not listed as proven (e.g., routine prophylactic post‑ERCP pancreatitis prevention without high‑dose regimen evidence, routine use for acute pancreatitis absent clear supportive trial justification, short bowel syndrome, persistent hyperinsulinemic hypoglycemia of infancy) is considered unproven or not medically necessary unless compelling evidence and documentation are provided.

Policy states somatostatin analogs are unproven for conditions not listed as proven due to lack of peer-reviewed evidence.

Somatostatin analogs (octreotide, lanreotide, pasireotide) are considered unproven when used to treat conditions that are not specifically listed as proven indications in this policy. The policy states that these agents are unproven for treating other conditions not listed as proven due to a lack of published clinical evidence of safety and/or efficacy in peer‑reviewed medical literature.

For neonatal or pediatric chylothorax, available evidence is limited to case reports, small series, and retrospective reviews; a Cochrane review found no randomized controlled trials and concluded that no practice recommendation can be made. Systematic reviews and narrative literature assessments report mixed results and call for randomized trials to determine safety, dosing, and efficacy.

Routine use of somatostatin or octreotide in the management of acute pancreatitis is not supported by convincing data. An American Gastroenterological Association technical review and large randomized trials reported no consistent benefit on mortality, organ failure, or secondary infections, and meta-analyses / reviews reach conflicting conclusions; therefore these agents are not recommended for routine management of acute pancreatitis.

Use of somatostatin analogs for refractory HIV/AIDS-related diarrhea is explicitly stated in the policy as unproven and not medically necessary and may be denied when presented as the sole rationale for therapy.

The policy explicitly lists the following uses as unproven / not medically necessary when they are the sole rationale for therapy: HIV‑AIDS‑related diarrhea, chylothorax, dumping syndrome, pancreatitis, persistent hyperinsulinemic hypoglycemia of infancy, prevention of postoperative complications following pancreatic surgery, and short bowel syndrome. Uses not specifically designated as proven in the indications section are similarly considered unproven due to insufficient published evidence.

Regarding prevention of post‑ERCP pancreatitis, the literature is mixed. Meta-analyses and large prospective studies have not consistently supported routine prophylactic use of somatostatin or octreotide; some analyses suggest benefit with higher total octreotide dosing (see evidence summaries), but current literature does not support routine prophylactic administration for ERCP‑related pancreatitis prevention.

The policy notes that use of Sandostatin (octreotide) or Sandostatin LAR should not be supported solely on assertions of improvement in clinical signs/symptoms, tumor size reduction, or quality of life without trial evidence. Product labeling for Sandostatin specifies a limitation of use that trials were not designed to demonstrate improvement in tumor size or rate of growth, and the policy aligns with labeling and evidence by requiring appropriate trial‑based or guideline‑supported indications for these endpoints.

As stated elsewhere in the policy, somatostatin analogs are considered unproven and not medically necessary for treatment of HIV‑AIDS‑related diarrhea. This exclusion is explicitly added to the coverage rationale and may result in coverage denial when that diagnosis is the sole basis for therapy.

Coding

Applicable HCPCS/J-codesHCPCS

J1930	Injection, lanreotide, 1 mg.
J1932	Injection, lanreotide, (cipla), 1 mg.
J2353	Injection, octreotide, depot form for intramuscular injection, 1 mg.
J2354	Injection, octreotide, non-depot form for subcutaneous or intravenous injection, 25 mcg.
J2502	Injection, pasireotide long acting, 1 mg

Applicable ICD-10 Codes (selected representative list)ICD-10

C7A.010	Malignant carcinoid tumor of the duodenum.
E22.0	Acromegaly and pituitary gigantism.
E24.0	Pituitary-dependent Cushing's disease.
E34.00	Carcinoid syndrome, unspecified.
I85.01	Esophageal varices with bleeding.
K52.0	Gastroenteritis and colitis due to radiation.
R19.7	Diarrhea, unspecified.

Applicable codes formatting changesmixed

No codes listed

Octreotide infusion duration comparison — key finding

Key findingIn a randomized trial (n=124) of cirrhotic patients with acute variceal bleeding, continuous octreotide infusion for 2 days versus 5 days showed no significant difference in early rebleeding rates (4.8% vs 8.6%).

Octreotide total dosage associated with prevention of post-ERCP pancreatitis

Total dose thresholdMeta-analyses stratified by total octreotide dose reported preventive efficacy against post-ERCP pancreatitis only when total dosage was ≥ 0.5 mg.

Biochemical control thresholds used in trials (GH and IGF‑1)

IGF-1 criterionTrials defined biochemical control as normalization of IGF‑1 for age and sex (IGF‑1 ≤ age‑/sex‑adjusted ULN).

Provider Actions and Authorization

Prior Authorization

Prior Authorization Required

Prior authorization is required for the listed HCPCS J-codes. Coverage and reimbursement remain dependent on the member-specific benefit plan; inclusion of codes in this policy does not guarantee coverage or payment. Providers should verify member benefits prior to ordering or administering therapy.

J1930 – Injection, lanreotide, 1 mg
J1932 – Injection, lanreotide (cipla), 1 mg
J2353 – Injection, octreotide, depot form, 1 mg
J2354 – Injection, octreotide, non-depot form, 25 mcg
J2502 – Injection, pasireotide long acting, 1 mg

Prior Authorization

Prior Authorization — Pasireotide (Signifor LAR) in Acromegaly

Prior authorization is required for pasireotide (Signifor LAR) when used to treat acromegaly. Requests must document the clinical rationale, prior treatments tried, and biochemical data (GH and IGF‑1). Be aware that pasireotide is associated with a high frequency of hyperglycemia-related adverse events, which should be addressed in the clinical record and monitoring plan.

Initial Therapy Criteria

Initial therapy / Administration

Initial therapy and administration considerations for long-acting formulations:

Administration conditions: Long-acting formulations (Sandostatin LAR, Signifor LAR, Somatuline Depot/Lanreotide Injection) are intended for deep intramuscular or deep subcutaneous administration at approximately 4‑week intervals and must be administered under physician supervision (office/clinic).

Sandostatin LAR is designed for IM injection every four weeks; product labeling requires physician supervision.

Prerequisite tolerability for LAR formulations: Sandostatin LAR is indicated in patients in whom initial treatment with Sandostatin subcutaneous injection has been shown to be effective and tolerated before switching to the long-acting depot formulation.

Per Sandostatin labeling.

Dosing interval and setting: Long-acting agents are typically dosed every 4 weeks; lanreotide 120 mg may be considered for extended dosing intervals in selected patients previously controlled on long-acting SRLs per registry and guideline data.

Continuation Therapy Criteria

Continuation therapy for pasireotide LAR

Continuation criteria for pasireotide LAR based on extension trial data and safety considerations:

Pasireotide LAR extension outcomes: Continuation may be supported when the member demonstrates maintained biochemical control or clear clinical benefit and tolerability; extension study data show biochemical control at month 25 in 48.6% (pasireotide LAR) vs 45.7% (octreotide LAR) with higher rates of hyperglycemia-related adverse events with pasireotide LAR.Documented maintained biochemical control (GH < =2.5 µg/L and normal IGF-1) or agent-specific targets

Hyperglycemia-related AEs were substantially more frequent with pasireotide LAR in extension studies; monitor and manage accordingly.

Monitoring and management: Ongoing therapy should include monitoring for hyperglycemia and glycemic management as indicated; continued treatment requires documentation of benefit and acceptable tolerability.none

High rates of pasireotide-associated hyperglycemia/diabetes reported in trials; caution required.

Step Therapy / Sequencing

Step	Requirement / clinical context	Evidence / policy note
1	Use after inadequate response to or when other primary therapies are not possible (e.g., surgery, radiotherapy, or dopamine agonist therapy for acromegaly)	Policy states agents are proven for acromegaly only in patients with inadequate response to or who cannot be treated with surgery, radiotherapy, or dopamine agonists; implies step use after primary therapies

Step	Requirement / clinical context	Evidence / policy note
1	Consider pasireotide LAR for patients inadequately controlled on long-acting octreotide or lanreotide	PAOLA and Colao randomized trials enrolled patients inadequately controlled on long-acting octreotide/lanreotide and showed superior biochemical control with pasireotide LAR versus continued octreotide/lanreotide; hyperglycemia was a common adverse event

Step	Requirement / clinical context	Evidence / policy note
1	Initial therapy: start with octreotide or lanreotide; if inadequate response, escalate to pasireotide or consider adding pegvisomant	Guidelines and trials support octreotide/lanreotide as common initial SRLs; pasireotide may be used for some uncontrolled patients; combination SRL plus pegvisomant shown effective with high biochemical control rates in selected patients

Step	Requirement / clinical context	Evidence / policy note
1	Use agents only for patients with inadequate response to or who cannot undergo prior definitive therapies (surgery and/or radiotherapy; for some agents, dopamine agonist therapy)	Policy language revised to specify proven use in acromegaly and other indications only for patients with inadequate response to or who are not candidates for surgery/radiotherapy (and where noted, dopamine agonists); coverage rationale and prior-authorizaton implications noted in policy history

Site of Care

Billing Rule

Office administration: physician supervision required for long‑acting IM injections

Long‑acting intramuscular injections such as Sandostatin LAR must be administered under physician supervision in an appropriate setting (office/clinic).

Sandostatin LAR is designed for intragluteal IM injection every four weeks and requires physician supervision
Document planned administration location and supervising physician in the medical record

Billing Rule

Administration setting: outpatient/infusion center for deep SC or IM injections every 4 weeks

Long‑acting injectable SRLs are administered by deep subcutaneous or intramuscular injection at 4‑week intervals in outpatient/injection center settings; document site of care accordingly.

Somatuline Depot and lanreotide injections are given by deep SC or IM injection at 4‑week intervals

Background

Somatostatin analogs are cyclic peptide agents that mimic endogenous somatostatin to inhibit the release of multiple hormones (including growth hormone, glucagon, and insulin) via somatostatin receptor binding. Long‑acting formulations (for example, Sandostatin LAR, Signifor LAR, Somatuline Depot / lanreotide) provide sustained receptor activation and are administered by supervised intramuscular or deep subcutaneous injection at multi‑week intervals. Pasireotide has broader somatostatin receptor subtype affinity (notably SSTR5) relevant to Cushing's disease, and labeling‑specific indications and adverse‑event profiles (particularly hyperglycemia) differ by agent.

Definitions

Sandostatin LAR — long‑acting IM octreotide formulation and administration note

FormulationSandostatin LAR is a long‑acting intramuscular formulation of octreotide designed for intragluteal injection every 4 weeks.

Clinical equivalenceMaintains the clinical and pharmacologic characteristics of immediate‑release octreotide with slow release from the injection site to reduce dosing frequency.

Administration requirementSandostatin LAR must be administered under physician supervision.

Pasireotide / Signifor LAR — mechanism and labeled uses summary

MechanismPasireotide (Signifor/Signifor LAR) is a somatostatin analogue that binds multiple somatostatin receptor subtypes (SSTR1–5), with clinical relevance from activity at SSTR5.

Labeled uses

Revision History

2025-04-01coverage_rationale_revisionLatest

Added language clarifying somatostatin analogs are unproven and not medically necessary for treating HIV-AIDS-related diarrhea; added statements that Sandostatin and Sandostatin LAR are proven for severe diarrhea and flushing from metastatic carcinoid tumors and for profuse watery diarrhea associated with VIPomas.

Policy Summary

PayerUnitedHealthcare

PolicySomatostatin Analogs (octreotide, lanreotide, pasireotide)

Policy CodePolicy IEXD0036.09

Change TypeCoverage rationale and indication clarificationscode removals

Effective DateApr 1, 2025

Next Review Date

Key ActionObtain prior authorization with diagnosis, prior therapies and response, and biochemical data (GH and IGF-1) to support medical necessity for long-acting somatostatin analog therapy.

SourceLink

On This Page

Documentation Required

Prior Authorization Documentation Requirements

Prior authorization requests for somatostatin analogs must include clinical documentation supporting medical necessity: the diagnosis, relevant prior therapies (surgery, radiotherapy, dopamine agonists, prior SRL dosing and response), and objective biochemical data where applicable (GH and IGF‑1 for acromegaly). Requests lacking required documentation may be delayed or denied.

Diagnosis and clinical history (e.g., acromegaly, carcinoid syndrome, VIPoma)
Prior surgical and/or radiation history for pituitary disease
Prior medical therapy: dopamine agonists (e.g., bromocriptine, cabergoline), octreotide/lanreotide dose and duration, response and tolerability
Laboratory data: baseline and recent GH and IGF‑1 values (with reference ranges and dates)

Prior Authorization

Coverage Rationale and Prior Authorization

Policy revisions clarify coverage rationale and prior authorization requirements: somatostatin analogs are proven for specified indications (see labeling) and are unproven/not medically necessary for certain uses (e.g., HIV-AIDS–related diarrhea). Coverage decisions must align with the member's benefit plan; UnitedHealthcare may apply additional utilization management tools.

Added: Somatostatin analogs unproven and not medically necessary for HIV-AIDS-related diarrhea (chunk 65)
Revised acromegaly language to limit use to patients with inadequate response to or who cannot undergo surgery/radiotherapy (chunks 4, 66)
UnitedHealthcare may use third‑party criteria (e.g., InterQual) in benefit administration (chunk 70)

Denial Risk

Potential Denial for Unproven Indications

Use of somatostatin analogs for indications that are unproven or not medically necessary (as listed in the policy) may be denied. Examples include HIV‑AIDS–related diarrhea and other uses lacking published evidence.

Potential denial for unproven indications: HIV-AIDS–related diarrhea, chylothorax, dumping syndrome, pancreatitis, persistent hyperinsulinemic hypoglycemia of infancy, prevention of postoperative complications following pancreatic surgery, short bowel syndrome (chunks 4, 5)
Requests for off‑label or unproven uses require robust supportive clinical evidence; absence may result in denial

Documentation Required

Document Trial Discontinuation Risks and Safety Signals

Clinical trial data show reasons for discontinuation and specific safety signals that may be relevant to coverage and ongoing treatment decisions. Documented discontinuation reasons and observed risks should be included in the prior authorization record when relevant.

Discontinuation reasons observed in trials: insufficient clinical response, death in a severely ill population (malignant bowel obstruction study) (chunk 18)
Adverse events to document: severe hyperglycemia, new or worsening diabetes, injection site reactions, diarrhea (chunks 18, 35, 36, 37)

Documentation Required

Acromegaly Trial Documentation

Acromegaly-specific trial evidence (e.g., PAOLA, Colao, and extension studies) demonstrating efficacy and the frequency of hyperglycemia-related adverse events should be included to support the medical necessity of pasireotide. Include trial outcomes (biochemical control rates, tumor volume responses) and safety profile in the request when applicable.

Include pertinent trial outcomes: biochemical control rates (GH <2.5 µg/L and normalized IGF‑1), tumor volume change, and duration of response (chunks 35, 36, 37)
Document monitoring and management plan for pasireotide-associated hyperglycemia

Note

Therapeutic Context (No Formal Step Therapy Specified)

Therapeutic context: there is no single formal step‑therapy sequence mandated by this policy. The policy references alternative therapies (e.g., dopamine agonists, octreotide/lanreotide) as established options, but does not prescribe a rigid step‑therapy requirement in all cases. Clinical judgment and member plan rules determine sequencing.

Alternatives to consider: dopamine agonists (bromocriptine, cabergoline), octreotide, lanreotide (chunks 4, 52)
Policy does not impose a formal universal step therapy pathway; check member plan for any plan-specific step therapy rules

Step Therapy

Step Therapy Considerations and Sequencing

Step therapy considerations and sequencing: consider intensifying SRL dose ± switching SRLs before advancing to pasireotide; combination therapy with pegvisomant is an alternative for patients not controlled on SRL monotherapy. If pasireotide plus pegvisomant is considered, document rationale and acknowledge that pegvisomant does not mitigate pasireotide-induced hyperglycemia.

Sequence options: optimize SRL dosing (octreotide/lanreotide), consider dose escalation or switch between SRLs prior to pasireotide (chunk 45)
Combination options: low‑dose SRL plus weekly pegvisomant or pasireotide plus pegvisomant for difficult‑to‑control patients (chunk 47)
Safety note: pegvisomant addition does not eliminate pasireotide-related hyperglycemia risk (chunk 47)

Step Therapy

Step / Prior Therapy Implications for Acromegaly

Step or prior therapy implications: policy language limits acromegaly coverage to patients with inadequate response to or who cannot undergo surgery/radiotherapy. Prior treatment history should be clearly documented to justify initiation of long‑acting formulations.

Operational implication: document prior surgical candidacy and outcomes or rationale why surgery/radiation is not an option
Justify escalation to long‑acting SRLs or pasireotide based on documented inadequate biochemical or clinical response to prior therapy

Initial therapy context for pasireotide in inadequate control

When considering pasireotide for patients inadequately controlled on octreotide/lanreotide:

Prior inadequate control: Member has documented inadequate biochemical control (GH and/or IGF-1 above trial-defined targets) despite at least 6 months of stable therapy with long-acting octreotide LAR (30 mg) or lanreotide (120 mg) as monotherapy, or documentation that prior SRL dosing/intensification was attempted and ineffective.Inadequate biochemical control defined per trials as GH > 2.5 µg/L and/or IGF-1 above age-adjusted ULN

PAOLA enrolled patients inadequately controlled on long-acting octreotide/lanreotide and randomized to pasireotide vs continued SSA; pasireotide showed superior biochemical control.

Glycemic risk assessment: Before initiating pasireotide, document baseline glycemic status and counsel/prescribe monitoring given high rates of hyperglycemia and diabetes observed in trials; consider alternative agents if hyperglycemia risk outweighs benefits.none

Pasireotide/pasireotide LAR trials report substantially higher hyperglycemia rates compared with octreotide/lanreotide.

Initial therapy — SRL initiation and dosing considerations

Initial somatostatin receptor ligand (SRL) selection and dosing considerations:

Initial SRL selection: Consider octreotide LAR or lanreotide (Somatuline Depot/Lanreotide Injection) as first‑line long‑acting SRL therapy for acromegaly per guideline recommendations; pasireotide may be considered for patients expected to benefit or uncontrolled on other SRLs but requires glycemic monitoring and justification.none

Endocrine Society and Pituitary Society guidance support initial use of octreotide or lanreotide; trials show pasireotide superior for some endpoints but with higher hyperglycemia risk.

Dose titration and monitoring: Titrate dose based on GH and IGF‑1 response per product labeling and monitor for adverse events (including hyperglycemia); consider addition of or switch to pegvisomant for inadequate responders or combination SRL + pegvisomant per guideline options.GH and IGF-1 monitoring per labeling

Combination therapy and pegvisomant options discussed in guidelines and long-term registries.

Initial therapy constraints

Indication-specific initial therapy constraints and prior therapy implications:

Acromegaly patients: Policy limits proven acromegaly indication to patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy (and for Sandostatin/Sandostatin LAR, who cannot be treated with dopamine agonist therapy when applicable); documentation of prior surgical/radiation attempts or contraindication is required for initial long-acting SRL coverage under this policy.

Policy history revisions clarified and narrowed acromegaly indications in 2025.

Cushing's disease patients: Pasireotide (Signifor/Signifor LAR) reserved for patients with Cushing's disease who are not surgical candidates or have persistent disease post-surgery; document prior surgical evaluation and reason surgery is not an option or was not curative.

Aligned with product labeling and policy revision language.

Continuation Therapy — general continuation when benefit maintained and tolerability acceptable

General continuation therapy criteria for long-acting somatostatin analogs:

Continuation criteria: Continued coverage is supported when there is documentation of maintained clinical benefit (biochemical control and/or symptom improvement), and adverse effects are tolerable or manageable. Dosing intervals may be extended in selected patients (e.g., extended-dosing intervals for lanreotide 120 mg) per registry and guideline data.IGF-1 < ULN and/or GH <= 2.5 µg/L depending on prior target

SODA registry and clinical trials support maintenance of biochemical control over 1–2 years; guidelines note extended dosing intervals may be effective in selected patients.

Discontinuation considerations: If adequate biochemical control or clinical benefit is not maintained, or intolerable adverse effects occur (including treatment‑induced hyperglycemia), therapy discontinuation or switching to alternative treatments (e.g., pegvisomant or combination therapy) should be considered and documented.

Guidelines and trials describe switching/add‑on strategies for inadequate responders.